| dc.creator |
Gürbüz, Nilgün |
|
| dc.date |
2022-02-01T00:00:00Z |
|
| dc.date.accessioned |
2022-05-10T11:28:29Z |
|
| dc.date.available |
2022-05-10T11:28:29Z |
|
| dc.identifier |
b613394e-d51a-49a0-a52e-65535c3f9e6f |
|
| dc.identifier |
10.5455/annalsmedres.2021.04.345 |
|
| dc.identifier |
https://avesis.sdu.edu.tr/publication/details/b613394e-d51a-49a0-a52e-65535c3f9e6f/oai |
|
| dc.identifier.uri |
http://acikerisim.sdu.edu.tr/xmlui/handle/123456789/96885 |
|
| dc.description |
<p style="margin-bottom: 0px; font-stretch: normal; font-size: 9px; line-height: normal; font-family: Helvetica;">Aim: Pancreatic ductal adenocarcinoma (PDAC) has high mortality and early stage metastatic potential.</p><p style="margin-bottom: 0px; font-stretch: normal; font-size: 9px; line-height: normal; font-family: Helvetica;">Thus, the developing new clinical approach and metastasis blocking strategy-based drugs are</p><p style="margin-bottom: 0px; font-stretch: normal; font-size: 9px; line-height: normal; font-family: Helvetica;">essential for cure of PDAC. In this study we aimed to investigate the effects of cell surface transmembrane</p><p style="margin-bottom: 0px; font-stretch: normal; font-size: 9px; line-height: normal; font-family: Helvetica;">glycoprotein CD44 on the regulation of key ECM proteins, integrin β1, fibronectin and</p><p style="margin-bottom: 0px; font-stretch: normal; font-size: 9px; line-height: normal; font-family: Helvetica;">collagen IV, in Panc-1 and MiaPaCa-2 cells.</p><p style="margin-bottom: 0px; font-stretch: normal; font-size: 9px; line-height: normal; font-family: Helvetica;">Materials and Methods: Followed by cell viability assay using MTS, fibronectin and collagen IV</p><p style="margin-bottom: 0px; font-stretch: normal; font-size: 9px; line-height: normal; font-family: Helvetica;">protein expression levels and integrin β1 mRNA level were analyzed in Panc-1 and MiaPaCa-2 cells</p><p style="margin-bottom: 0px; font-stretch: normal; font-size: 9px; line-height: normal; font-family: Helvetica;">treated with 50 nM negative siRNA and CD44 siRNA for 72 h using western blot and RT-PCR, respectively.</p><p style="margin-bottom: 0px; font-stretch: normal; font-size: 9px; line-height: normal; font-family: Helvetica;">Results: Based on our findings, the downregulation of CD44 using specific siRNA led to decrease</p><p style="margin-bottom: 0px; font-stretch: normal; font-size: 9px; line-height: normal; font-family: Helvetica;">fibronectin and collagen IV proteins expressions, and also Integrin β1 mRNA expression in both</p><p style="margin-bottom: 0px; font-stretch: normal; font-size: 9px; line-height: normal; font-family: Helvetica;">Panc-1 and MiaPaCa-2 cell lines.</p><p style="margin-bottom: 0px; font-stretch: normal; font-size: 9px; line-height: normal; font-family: Helvetica;">Conclusion: CD44 siRNA based therapies have effective role to inhibit ECM degradation in PDAC</p><p style="margin-bottom: 0px; font-stretch: normal; font-size: 9px; line-height: normal; font-family: Helvetica;">progression. CD44 is also promising target for against PDAC through inhibiting migration, invasion</p><p style="margin-bottom: 0px; font-stretch: normal; font-size: 9px; line-height: normal; font-family: Helvetica;">and metastasis steps.</p> |
|
| dc.language |
eng |
|
| dc.rights |
info:eu-repo/semantics/openAccess |
|
| dc.title |
Downregulation of CD44 regulates extracellular matrix degradation in human pancreatic ductal adenocarcinoma cells |
|
| dc.type |
info:eu-repo/semantics/article |
|